According to Emergent BioSolutions
's latest financial reports the company has a price-to-book ratio of 0.3495.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.1918 | -54.83% |
2022-12-31 | 0.4246 | -70.74% |
2021-12-31 | 1.45 | -55.78% |
2020-12-31 | 3.28 | 28.07% |
2019-12-31 | 2.56 | -14.65% |
2018-12-31 | 3.00 | 18.13% |
2017-12-31 | 2.54 | 13.93% |
2016-12-31 | 2.23 | -6.62% |
2015-12-31 | 2.39 | 28.7% |
2014-12-31 | 1.86 | 7.84% |
2013-12-31 | 1.72 | 32.27% |
2012-12-31 | 1.30 | -10.43% |
2011-12-31 | 1.45 | -33.92% |
2010-12-31 | 2.20 | 27.95% |
2009-12-31 | 1.72 | -56.15% |
2008-12-31 | 3.92 | 345.58% |
2007-12-31 | 0.8795 | -60.46% |
2006-12-31 | 2.22 | |
2005-12-31 | N/A | |
2004-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Pfizer PFE | 1.78 | 409.14% | ๐บ๐ธ USA |
Merck MRK | 8.77 | 2,410.34% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 5.53 | 1,482.07% | ๐ฌ๐ง UK |
Soligenix SNGX | 2.25 | 544.17% | ๐บ๐ธ USA |
SIGA Technologies SIGA | 2.83 | 709.00% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | 6.19 | 1,670.87% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 2.30 | 557.13% | ๐ฎ๐ฑ Israel |